US Dollar vs MXN

Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.

Regístrate

XLRN

Acceleron Pharma (XLRN)

Acceleron Pharma Inc

Fecha:

Regulatory News

Text Search:

Ordernar por:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:XLRN

<< Anterior 1 2 3 4 5 6 7 8 9 10 11 12 Próxima >

Fecha	Hora	Fuente	Título	Símbolo	Compañía
12/07/2018	06:00	Business Wire	Acceleron Receives FDA Orphan Drug Designation for ACE-083 in Facioscapulohumeral Muscular Dystrophy	NASDAQ:XLRN	Acceleron Pharma Inc
10/07/2018	16:28	Dow Jones News	Health Care Shares Move Higher as Focus Shifts to Earnings -- Health Care Roundup	NASDAQ:XLRN	Acceleron Pharma Inc
09/07/2018	17:36	Dow Jones News	Celgene, Acceleron Say Trial on Blood-Disorder Drug Yields Positive Results -- Update	NASDAQ:XLRN	Acceleron Pharma Inc
09/07/2018	17:20	Dow Jones News	Celgene and Acceleron Announce Positive Results From Blood-Disorder Drug Trials	NASDAQ:XLRN	Acceleron Pharma Inc
09/07/2018	16:15	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:XLRN	Acceleron Pharma Inc
09/07/2018	15:52	Business Wire	Celgene & Acceleron Announce Luspatercept Achieved Primary & All Key Secondary Endpoints in Phase III ‘BELIEVE’ Study in ...	NASDAQ:XLRN	Acceleron Pharma Inc
05/07/2018	15:49	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:XLRN	Acceleron Pharma Inc
05/07/2018	15:46	Edgar (US Regulatory)	Initial Statement of Beneficial Ownership (3)	NASDAQ:XLRN	Acceleron Pharma Inc
05/07/2018	15:30	Business Wire	Acceleron Appoints Robert K. Zeldin, M.D., Chief Medical Officer	NASDAQ:XLRN	Acceleron Pharma Inc
28/06/2018	15:30	Business Wire	Celgene & Acceleron Announce Luspatercept Achieved Primary & Key Secondary Endpoints in Phase III ‘MEDALIST’ Study in Pat...	NASDAQ:XLRN	Acceleron Pharma Inc
26/06/2018	06:00	Business Wire	Acceleron to Present Preliminary Data on ACE-083 at the 2018 Annual Meeting of the Peripheral Nerve Society	NASDAQ:XLRN	Acceleron Pharma Inc
15/06/2018	06:00	Business Wire	Acceleron Announces Updated Results from Ongoing Phase 2 Trials of Luspatercept in Beta-Thalassemia at the 23rd Congress of t...	NASDAQ:XLRN	Acceleron Pharma Inc
04/06/2018	06:00	Business Wire	Acceleron Announces Updated Results from Ongoing Phase 2 Trials of Luspatercept in Myelodysplastic Syndromes at the ASCO 2018...	NASDAQ:XLRN	Acceleron Pharma Inc
22/05/2018	06:00	Business Wire	Acceleron Announces Initiation of PULSAR Phase 2 Trial of Sotatercept in Pulmonary Arterial Hypertension	NASDAQ:XLRN	Acceleron Pharma Inc
17/05/2018	08:21	Business Wire	Acceleron Announces Presentations on Luspatercept at the 23rd Congress of the European Hematology Association	NASDAQ:XLRN	Acceleron Pharma Inc
08/05/2018	15:29	Edgar (US Regulatory)	Quarterly Report (10-q)	NASDAQ:XLRN	Acceleron Pharma Inc
08/05/2018	15:01	Business Wire	Acceleron Reports First Quarter 2018 Operating and Financial Results	NASDAQ:XLRN	Acceleron Pharma Inc
02/05/2018	06:00	Business Wire	Acceleron to Participate in Two Healthcare Investor Conferences in May	NASDAQ:XLRN	Acceleron Pharma Inc
01/05/2018	06:00	Business Wire	Acceleron Receives FDA Fast Track Designation for ACE-083 in Facioscapulohumeral Muscular Dystrophy (FSHD)	NASDAQ:XLRN	Acceleron Pharma Inc
30/04/2018	06:00	Business Wire	Acceleron to Webcast First Quarter 2018 Operating and Financial Results on May 8, 2018	NASDAQ:XLRN	Acceleron Pharma Inc
26/04/2018	07:00	Business Wire	Acceleron Announces ACE-083 Phase 2 Trial Presentation at the American Academy of Neurology 70th Annual Meeting	NASDAQ:XLRN	Acceleron Pharma Inc
26/04/2018	06:00	Business Wire	Acceleron Announces Presentations on Lead Product Candidate Luspatercept at the 2018 American Society of Clinical Oncology An...	NASDAQ:XLRN	Acceleron Pharma Inc
13/04/2018	15:21	Edgar (US Regulatory)	Additional Proxy Soliciting Materials (definitive) (defa14a)	NASDAQ:XLRN	Acceleron Pharma Inc
13/04/2018	15:19	Edgar (US Regulatory)	Proxy Statement (definitive) (def 14a)	NASDAQ:XLRN	Acceleron Pharma Inc
12/03/2018	06:00	Business Wire	Acceleron to Host Educational Webinar with Leading Clinicians to Provide an Overview of Pulmonary Arterial Hypertension (PAH)...	NASDAQ:XLRN	Acceleron Pharma Inc
28/02/2018	06:04	Business Wire	Acceleron Announces Publication of ACE-083 Phase 1 Trial Results in Muscle & Nerve	NASDAQ:XLRN	Acceleron Pharma Inc
27/02/2018	16:49	Edgar (US Regulatory)	Securities Registration: Employee Benefit Plan (s-8)	NASDAQ:XLRN	Acceleron Pharma Inc
27/02/2018	15:27	Edgar (US Regulatory)	Annual Report (10-k)	NASDAQ:XLRN	Acceleron Pharma Inc
27/02/2018	15:05	Business Wire	Acceleron Reports Fourth Quarter and Full Year 2017 Operating and Financial Results	NASDAQ:XLRN	Acceleron Pharma Inc
20/02/2018	06:00	Business Wire	Acceleron to Webcast Fourth Quarter and Full Year 2017 Operating and Financial Results on February 27, 2018	NASDAQ:XLRN	Acceleron Pharma Inc

Showing the most relevant articles for your search:NASDAQ:XLRN

<< Anterior 1 2 3 4 5 6 7 8 9 10 11 12 Próxima >

Verizon Communications

BNP Paribas (QX)

Energy Select Sector SPDR

Financial Select Sector

Gold vs US Dollar

American Express

Delayed Upgrade Clock

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones